FORCE's eXamining the Relevance of Articles for You (XRAY) program looks behind the headlines of cancer news to help you understand what the research means for you.
XRAY is a reliable source of hereditary cancer research-related news and information.
Learn more about the XRAY program
All XRAYs
Relevance: Medium-High
Strength of Science: High
Research Timeline: Post Approval
Guideline : Guidelines on exercise, diet, and weight during cancer treatment
Relevance: Medium-High
Strength of Science: High
Research Timeline: Post Approval
Most relevant for: People currently undergoing treatment for cancer
Most professional guidelines on exercise, diet and weight management have focused on the health of the general population and cancer survivors. The American Society of Clinical Oncology (ASCO) has now published evidence-based recommendations for exercise, diet and weight specifically for people who are in active treatment for cancer. (Posted 11/29/22) Este artículo está disponible en español.
Read More
Relevance: Medium-High
Strength of Science: High
Research Timeline: Post Approval
Study : Liquid biopsies personalize early-stage colon cancer treatment
Relevance: Medium-High
Strength of Science: High
Research Timeline: Post Approval
Most relevant for: People with early-stage colorectal cancer
Liquid biopsies look for DNA or other products from cancer cells in the blood or other body fluids. These tests may be used to help find cancer recurrence early, monitor response to treatment or guide treatment selection for people diagnosed with cancer. This study looked at a type of liquid biopsy called “circulating tumor” (ctDNA) to identify people with early-stage colon cancer who can safely skip chemotherapy after surgery. (Posted 11/22/22) Este artículo está disponible en español.
Read More
Relevance: Medium-High
Strength of Science: High
Research Timeline: Human Research
Study : Promising early results for people with DNA mismatch repair deficient rectal cancer
Relevance: Medium-High
Strength of Science: High
Research Timeline: Human Research
Most relevant for: People with rectal cancer with high mutational burden or mismatch repair problems including people with Lynch syndrome.
A small research study tested the usefulness of the immunotherapy drug dostarlimab for treating locally advanced rectal cancer with a biomarker known as “dMMR” (DNA mismatch repair deficient). None of the participants had evidence of cancer six months later; some remained cancer free for up to 25 months). Many participants had Lynch syndrome. The remarkable response to this treatment may allow people with this particular subtype of rectal cancer to avoid potentially life-changing rectal surgery. (Posted 11/14/22) Este artículo está disponible en español.
Read More
Relevance: High
Strength of Science: Medium-High
Research Timeline: Human Research
Study : Prostate cancer screening may benefit people with Lynch syndrome
Relevance: High
Strength of Science: Medium-High
Research Timeline: Human Research
Most relevant for: People with Lynch syndrome
Initial results from the IMPACT trial show that PSA testing to screen for prostate cancer in people with Lynch syndrome can detect aggressive early prostate cancers. These findings support the use of PSA screening in men with Lynch syndrome, particularly men with an inherited mutation in an MSH2 or MSH6 gene. (Posted 11/10/22)
Este artículo está disponible en español.
Read More
Relevance: Medium-High
Strength of Science: Medium
Research Timeline: Post Approval
Study : More is not better: PARP dose can be safely reduced for people with ovarian cancer
Relevance: Medium-High
Strength of Science: Medium
Research Timeline: Post Approval
Most relevant for: People taking a PARP inhibitor for ovarian cancer maintenance therapy
Maintenance therapy with a PARP inhibitor is now the standard of care for many people with advanced or recurrent ovarian cancer. However, PARP inhibitors may have significant side effects. This study shows that reducing the dose of a PARP inhibitor does not affect survival. (Posted 11/8/22)
Este artículo está disponible en español.
Read More
Update : Strategies for managing pancreatic cancer pain
Most relevant for: People with pancreatic cancer who are dealing with related pain.
Abdominal pain is often a severe, ongoing symptom of pancreatic cancer, yet little research has been done on how to best reduce this pain. The authors of this review discuss current strategies for managing cancer-related pain and their effectiveness. (Posted 10/31/22)
Este artículo está disponible en español.
Read More
Relevance: Medium-High
Strength of Science: High
Research Timeline: Post Approval
Study : Resistant starch may help prevent some cancers in people with Lynch syndrome
Relevance: Medium-High
Strength of Science: High
Research Timeline: Post Approval
Most relevant for: People with Lynch syndrome and people with a personal and/or family history that suggests Lynch syndrome
This study looked at whether a type of nutrient known as resistant starch could lower the risk of cancers in people with Lynch Syndrome. Researchers found that resistant starch can reduce the risk of non-colorectal cancers but not colorectal cancer. (Posted 10/17/22)
Este artículo está disponible en español.
Read More
Relevance: Medium-High
Strength of Science: Medium-High
Study : Teens and young adults respond well to learning about familial cancer risk
Relevance: Medium-High
Strength of Science: Medium-High
Most relevant for: Mothers who have had genetic testing for BRCA1 or BRCA2 whether or not they have been diagnosed with breast or ovarian cancer
Little is known about how awareness of hereditary cancer in a high-risk family affects the quality of life of teens and young adults. This study looked at the lifestyle choices, cancer awareness and quality of life of adolescents and young adults whose mothers had undergone testing for a BRCA mutation. (Posted 10/11/2022) Este artículo está disponible en español.
Read More
Update : PARP inhibitors withdrawn as third-line or later treatment for recurrent ovarian cancer
Most relevant for: people with recurrent ovarian cancer who have received 3 or more prior lines of treatment and who have an inherited or tumor mutation in BRCA1 or BRCA2 or whose tumor is HRD positive
Survival data from a clinical trial signaled that PARP inhibitors may not work as well as chemotherapy for patients with recurrent ovarian cancer who have received three or more lines of treatment. As a result, FDA approvals have been withdrawn for PARP inhibitors in this setting. This does not affect PARP inhibitor approvals for use as maintenance therapy for ovarian cancer. (Posted 10/4/22)
Este artículo está disponible en español.
Read More
Relevance: High
Strength of Science: Medium-High
Research Timeline: Post Approval
Study : Acupuncture may ease breast cancer treatment side effects
Relevance: High
Strength of Science: Medium-High
Research Timeline: Post Approval
Most relevant for: People considering acupuncture for managing breast cancer treatment symptoms.
Acupuncture can ease some symptoms of breast cancer treatment. Multiple studies found that acupuncture is a safe and effective strategy to manage certain symptoms but also called for more rigorous research on the topic. (Posted 9/28/22) Este artículo está disponible en español.
Read More